{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T14:35:07Z","timestamp":1718202907387},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,28]]},"DOI":"10.7759\/cureus.22677","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T10:30:24Z","timestamp":1646044224000},"source":"Crossref","is-referenced-by-count":3,"title":["Depression in Fibromyalgia Patients May Require Low-Dose Naltrexone to Respond: A Case Report"],"prefix":"10.7759","author":[{"given":"Jagoda","family":"Siembida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v67n0807","article-title":"Comorbidity of fibromyalgia and psychiatric disorders","volume":"67","author":"Arnold LM","year":"2006","unstructured":"Arnold LM, Hudson JI, Keck PE, Auchenbach MB, Javaras KN, Hess EV. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry. 2006, 67:1219-25. 10.4088\/jcp.v67n0807","journal-title":"J Clin Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2018.20.1\/whauser","article-title":"Facts and myths pertaining to fibromyalgia","volume":"20","author":"H\u00e4user W","year":"2018","unstructured":"H\u00e4user W, Fitzcharles MA. Facts and myths pertaining to fibromyalgia. Dialogues Clin Neurosci. 2018, 20:53-62. 10.31887\/DCNS.2018.20.1\/whauser","journal-title":"Dialogues Clin Neurosci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2011.11.006","article-title":"Is fibromyalgia an endocrine\/endorphin deficit disorder? Is low dose naltrexone a new treatment option?","volume":"53","author":"Ramanathan S","year":"2012","unstructured":"Ramanathan S, Panksepp J, Johnson B. Is fibromyalgia an endocrine\/endorphin deficit disorder? Is low dose naltrexone a new treatment option?. Psychosomatics. 2012, 53:591-4. 10.1016\/j.psym.2011.11.006","journal-title":"Psychosomatics"},{"key":"ref4","article-title":"Fibromyalgia, autism, and opioid addiction as natural and induced disorders of the endogenous opioid hormonal system","volume":"18","author":"Johnson B","year":"2014","unstructured":"Johnson B, Ulberg S, Shivale S, Donaldson J, Milczarski B, Faraone SV. Fibromyalgia, autism, and opioid addiction as natural and induced disorders of the endogenous opioid hormonal system. Discov Med. 2014, 18:209-20.","journal-title":"Discov Med"},{"key":"ref5","article-title":"Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone","volume":"26","author":"Oaks Z","year":"2018","unstructured":"Oaks Z, Stage A, Middleton B, Faraone S, Johnson B. Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone. Discov Med. 2018, 26:197-206.","journal-title":"Discov Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.593842","article-title":"The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia","volume":"12","author":"Jackson D","year":"2021","unstructured":"Jackson D, Singh S, Zhang-James Y, Faraone S, Johnson B. The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia. Front Psychiatry. 2021, 12:593842. 10.3389\/fpsyt.2021.593842","journal-title":"Front Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1535370218817746","article-title":"Intermittent blockade of OGFr and treatment of autoimmune disorders","volume":"243","author":"Zagon IS","year":"2018","unstructured":"Zagon IS, McLaughlin PJ. Intermittent blockade of OGFr and treatment of autoimmune disorders. Exp Biol Med (Maywood). 2018, 243:1323-30. 10.1177\/1535370218817746","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.657952","article-title":"Autism case report: cause and treatment of \"high opioid tone\" autism","volume":"12","author":"Anugu V","year":"2021","unstructured":"Anugu V, Ringhisen J, Johnson B. Autism case report: cause and treatment of \"high opioid tone\" autism. Front Psychol. 2021, 12:657952. 10.3389\/fpsyg.2021.657952","journal-title":"Front Psychol"},{"key":"ref9","article-title":"Depression and addiction","author":"Johnson B","year":"2009","unstructured":"Johnson B. Depression and addiction. Depression: treatment strategies and management, second edition. Schwartz TL, Petersen TJ (ed): Taylor & Francis, New York, NY; 2009."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-8315.2008.00046.x","article-title":"Transference focused psychotherapy: overview and update","volume":"89","author":"Kernberg OF","year":"2008","unstructured":"Kernberg OF, Yeomans FE, Clarkin JF, Levy KN. Transference focused psychotherapy: overview and update. Int J Psychoanal. 2008, 89:601-20. 10.1111\/j.1745-8315.2008.00046.x","journal-title":"Int J Psychoanal"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6541798","article-title":"Current and emerging pharmacotherapy for fibromyalgia","volume":"2020","author":"Tzadok R","year":"2020","unstructured":"Tzadok R, Ablin JN. Current and emerging pharmacotherapy for fibromyalgia. Pain Res Manag. 2020, 2020:6541798. 10.1155\/2020\/6541798","journal-title":"Pain Res Manag"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/art.37734","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"Younger J","year":"2013","unstructured":"Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013, 65:529-38. 10.1002\/art.37734","journal-title":"Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"Younger J","year":"2009","unstructured":"Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009, 10:663-72. 10.1111\/j.1526-4637.2009.00613.x","journal-title":"Pain Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.08.029","article-title":"Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants","volume":"208","author":"Mischoulon D","year":"2017","unstructured":"Mischoulon D, Hylek L, Yeung AS, et al.. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017, 208:6-14. 10.1016\/j.jad.2016.08.029","journal-title":"J Affect Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines5020020","article-title":"Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology","volume":"5","author":"Kia S","year":"2017","unstructured":"Kia S, Choy E. Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines. 2017, 5:10.3390\/biomedicines5020020","journal-title":"Biomedicines"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011735","article-title":"Selective serotonin reuptake inhibitors for fibromyalgia syndrome","author":"Walitt B","year":"2015","unstructured":"Walitt B, Urr\u00fatia G, Nishishinya MB, Cantrell SE, H\u00e4user W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev. 2015, CD011735. 10.1002\/14651858.CD011735","journal-title":"Cochrane Database Syst Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51569-z","article-title":"Changes in the consumption of antiepileptics and psychotropic medicines after starting low dose naltrexone: a nation-wide register-based controlled before-after study","volume":"9","author":"Raknes G","year":"2019","unstructured":"Raknes G, Sm\u00e5brekke L. Changes in the consumption of antiepileptics and psychotropic medicines after starting low dose naltrexone: a nation-wide register-based controlled before-after study. Sci Rep. 2019, 9:15085. 10.1038\/s41598-019-51569-z","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/art.21008","article-title":"The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort","volume":"52","author":"Giesecke T","year":"2005","unstructured":"Giesecke T, Gracely RH, Williams DA, Geisser ME, Petzke FW, Clauw DJ. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum. 2005, 52:1577-84. 10.1002\/art.21008","journal-title":"Arthritis Rheum"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger J","year":"2014","unstructured":"Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014, 33:451-9. 10.1007\/s10067-014-2517-2","journal-title":"Clin Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.539777","article-title":"Single-subject research in psychiatry: facts and fictions","volume":"11","author":"Zuidersma M","year":"2020","unstructured":"Zuidersma M, Riese H, Snippe E, Booij SH, Wichers M, Bos EH. Single-subject research in psychiatry: facts and fictions. Front Psychiatry. 2020, 11:539777. 10.3389\/fpsyt.2020.539777","journal-title":"Front Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/85269-depression-in-fibromyalgia-patients-may-require-low-dose-naltrexone-to-respond-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:50Z","timestamp":1707507590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/85269-depression-in-fibromyalgia-patients-may-require-low-dose-naltrexone-to-respond-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.22677","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}